PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.73%
Negative EBIT growth while AGEN is at 19.69%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-5.73%
Negative operating income growth while AGEN is at 19.69%. Joel Greenblatt would press for urgent turnaround measures.
-4.82%
Negative net income growth while AGEN stands at 12.20%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-5.05%
Negative EPS growth while AGEN is at 25.25%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-5.05%
Negative diluted EPS growth while AGEN is at 25.25%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3274.19%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-3274.19%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.86%
10Y OCF/share CAGR above 1.5x AGEN's 22.72%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
47.86%
5Y OCF/share CAGR at 50-75% of AGEN's 77.23%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
47.86%
3Y OCF/share CAGR at 75-90% of AGEN's 58.31%. Bill Ackman would press for improvements in margin or overhead to catch up.
60.77%
Net income/share CAGR above 1.5x AGEN's 35.42% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
60.77%
5Y net income/share CAGR at 75-90% of AGEN's 69.63%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
60.77%
3Y net income/share CAGR 1.25-1.5x AGEN's 48.55%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.11%
Negative asset growth while AGEN invests at 29.39%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.64%
We have a declining book value while AGEN shows 43.62%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
8.65%
We have some new debt while AGEN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
6.08%
We expand SG&A while AGEN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.